Tasosartan-WAY-ANA-756-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETasosartanCat. No.: HY-A0250CAS No.: 145733-36-4Synonyms: WAY-ANA 756分式: CHNO分量: 411.46作靶点: Angiotensin Receptor作通路: GPCR/G Protein储存式: Powder -20C 3 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 125 mg/mL (303.80 mM

2、; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.4304 mL 12.1518 mL 24.3037 mL5 mM 0.4861 mL 2.4304 mL 4.8607 mL10 mM 0.2430 mL 1.2152 mL 2.4304 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液

3、可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (5.06 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (5.06 mM); Clear solution3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.08 mg/mL

4、(5.06 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 Tasosartan种长效的管紧张素 II (AngII) 受体拮抗剂。IC50 & Target Angiotensin II (AngII) receptor 1体外研究 Tasosartan is an orally active nonpeptide AngII antagonist that has demonstrates specific and selective AT1receptor

5、 antagonistic activity in vitro. IC50 for inhibition of specific binding of 125I-AngII to rat adrenalmembrane in the absence of proteins in binding buffer is 1.20.6 nM 1.体内研究 Administration of Tasosartan at doses of 1.0 and 3.0 mg/kg (iv) significantly (p 2.PROTOCOLAnimal Rats 2Administration 2 Pres

6、sor response to angiotensin-II administration in four groups of rats (n=3-5 each, weighing 3438 g).Each rat is subjected to four separate bolus injections of angiotensin-II following the introduction of either thevehicle or graded doses of Tasosartan (0.3, 1.0, or 3.0 mg/kg, iv) 2.MCE has not indepe

7、ndently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Maillard MP, et al. Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. JPharmacol Exp Ther. 2000 Nov;295(2):649-54.2. Elokdah HM, et al. Novel human metabolites of the angiotensin-II antagonist Tasosartan and their pharmacological effects. Bioorg MedChem Lett. 2002 Aug 5;12(15):1967-71.McePdfHeightCaution: Product has not been fully validated for medical applications.For res